New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 13, 2012
10:24 EDTAMT, ABC, CELG, ITW, NOK, PPL, JBHTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Tower (AMT) downgraded to Neutral from Overweight at Piper Jaffray... AmerisourceBergen (ABC) downgraded to Equal Weight from Overweight at Morgan Stanley... Celgene (CELG) downgraded to Hold from Buy at Auriga... Illinois Tool Works (ITW) downgraded to Underweight from Equal Weight at Morgan Stanley... Nokia (NOK) downgraded to Equal Weight from Overweight at Barclays... PPL Corp. (PPL) downgraded to Buy from Conviction Buy at Goldman... J.B. Hunt (JBHT) downgraded to Neutral from Buy at Sterne Agee.
News For AMT;ABC;CELG;ITW;NOK;PPL;JBHT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 23, 2014
07:33 EDTCELGCelgene raises FY14 adjusted EPS view to $3.65-$3.70 from $3.60-$3.65
Subscribe for More Information
07:32 EDTCELGCelgene reports Q3 REVLIMID sales $1.3B
Subscribe for More Information
07:32 EDTCELGCelgene reports Q3 adjusted EPS 97c, consensus 95c
Subscribe for More Information
06:47 EDTNOKMicrosoft aims to ditch Nokia title from Lumia devices, Reuters says
Subscribe for More Information
06:05 EDTNOKApple defeats GPNE civil patent suit, Re/code reports
Subscribe for More Information
05:19 EDTNOKNokia reports Q3 Non-IFRS EPS EUR 0.09 vs. EUR 0.06 last year
Subscribe for More Information
October 22, 2014
15:37 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
11:55 EDTCELGStocks with call strike movement; YHOO CELG
Yahoo (YHOO) January 48 call option implied volatility decreased 6% to 32, Celgene (CELG) April 110 call option implied volatility increased 2% to 32 according to IVolatility.
11:38 EDTCELGBiogen retreats after Tecfidera sales miss, patient death reported
Subscribe for More Information
11:01 EDTCELGBiogen trading lower on slower growth, PML case, says Deutsche Bank
Deutsche Bank attributes the pullback in shares of Biogen (BIIB) to slower sequential revenue growth and the one PML case with Tecfidera disclosed on today's earnings call. Deutsche believes investors are now favoring Celgene (CELG) over Biogen due to near term headline risks. The firm says it likes Celgene more as well due its pipeline, but keeps a Buy rating on Biogen.
06:39 EDTNOKMicrosoft Lumia to replace Nokia brand, The Verge reports
Microsoft plans to make Microsoft Lumia the new brand name that takes the place of Nokia for the software maker, reports The Verge. Nokia still exists as a separate company without its phones business, focusing on mapping and network infrastructure. Reference Link
October 21, 2014
09:23 EDTCELGCelgene GED-0301 said to have 67% 12-week remission at high dose in trial
Subscribe for More Information
08:07 EDTITWIllinois Tool Works raises FY14 EPS view to $4.57-$4.65 from $4.50-$4.62
Subscribe for More Information
08:07 EDTITWIllinois Tool Works sees Q4 EPS $1.07-$1.15, consensus $1.13
Sees Q4 revenue flat due to currency translation effects, consensus $3.64B.
08:04 EDTITWIllinois Tool Works reports Q3 EPS $1.28, consensus $1.23
Subscribe for More Information
October 20, 2014
15:36 EDTITWNotable companies reporting before tomorrow's open
Subscribe for More Information
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
October 17, 2014
13:18 EDTCELGLeerink's biotech analyst holds an analyst/industry conference call
Subscribe for More Information
10:00 EDTABCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use